Lantern Pharma (LTRN) 10-Q 7 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 01, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-39318
Entity Registrant Name	Lantern Pharma Inc.
Entity Central Index Key	0001763950
Entity Tax Identification Number	46-3973463
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1920 McKinney Avenue
Entity Address, Address Line Two	7th Floor
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75201
City Area Code	(972)
Local Phone Number	277-1136
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	LTRN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		10,857,040

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
CURRENT ASSETS
Cash and cash equivalents	$ 39,257,887	$ 51,524,295
Restricted cash	541,180
Marketable securities	18,568,725	19,201,152
Prepaid expenses and other current assets	3,651,968	1,990,953
Total current assets	62,019,760	72,716,400
Property and equipment, net	43,813	30,245
Operating lease right-of-use assets	82,918	185,943
Restricted cash		1,000,000
Other assets	17,889	17,889
TOTAL ASSETS	62,164,380	73,950,477
CURRENT LIABILITIES
Accounts payable and accrued expenses	3,046,972	2,174,109
Operating lease liabilities, current	92,023	152,058
Total current liabilities	3,138,995	2,326,167
Operating lease liabilities, net of current portion		52,890
TOTAL LIABILITIES	3,138,995	2,379,057
COMMITMENTS AND CONTINGENCIES (NOTE 4)
STOCKHOLDERS’ EQUITY
Preferred Stock – Par Value (1,000,000 authorized at September 30, 2022 and December 31, 2021; $.0001 par value) (Zero shares issued and outstanding at September 30, 2022 and December 31, 2021)
Common Stock – Par Value (25,000,000 authorized at September 30, 2022 and December 31, 2021; $.0001 par value) (10,857,040 shares issued and outstanding at September 30, 2022; 11,088,835 shares issued and outstanding at December 31, 2021)	1,086	1,109
Additional paid-in capital	95,361,099	96,685,924
Accumulated other comprehensive loss	(435,035)	(92,689)
Accumulated deficit	(35,901,765)	(25,022,924)
Total stockholders’ equity	59,025,385	71,571,420
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 62,164,380	$ 73,950,477

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common stock, shares authorized	25,000,000	25,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares issued	10,857,040	11,088,835
Common stock, shares outstanding	10,857,040	11,088,835

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
General and administrative	$ 1,442,961	$ 1,184,486	$ 4,255,119	$ 3,671,945
Research and development	702,296	2,964,391	6,351,356	5,408,320
Total operating expenses	2,145,257	4,148,877	10,606,475	9,080,265
Loss from operations	(2,145,257)	(4,148,877)	(10,606,475)	(9,080,265)
Interest income	52,224	77,219	129,671	125,108
Other (expense) income, net	(171,648)	17,679	(402,037)	132,402
NET LOSS	$ (2,264,681)	$ (4,053,979)	$ (10,878,841)	$ (8,822,755)
Net loss per share of common shares, basic and diluted	$ (0.21)	$ (0.36)	$ (1)	$ (0.82)
Weighted-average number of common shares outstanding, basic and diluted	10,838,888	11,186,259	10,848,402	10,818,201

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
NET LOSS	$ (2,264,681)	$ (4,053,979)	$ (10,878,841)	$ (8,822,755)
Other comprehensive loss, net of tax
Unrealized loss on available-for-sale securities, net of tax	(118,572)	(55,124)	(394,843)	(102,689)
Unrealized gain on foreign currency translation	32,018		52,497
Other comprehensive loss, net of tax	(86,554)	(55,124)	(342,346)	(102,689)
Comprehensive loss	$ (2,351,236)	$ (4,109,103)	$ (11,221,187)	$ (8,925,444)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholder's Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020		$ 622	$ 32,358,068		$ (12,659,895)	$ 19,698,795
Beginnig balance, shares at Dec. 31, 2020		6,220,927
Common stock issued in equity financing, net of issuance costs		$ 493	64,166,361			64,166,854
Common stock issued in equity financing, net of issuance costs, shares		4,928,571
Common stock issued from warrant and option exercises		$ 3	72,750			72,753
Common stock issued from warrant and option exercises, shares		31,949
Stock-based compensation			245,519			245,519
Net loss					(2,452,295)	(2,452,295)
Ending balance, value at Mar. 31, 2021		$ 1,118	96,842,698		(15,112,190)	81,731,626
Ending balance, shares at Mar. 31, 2021		11,181,447
Beginning balance, value at Dec. 31, 2020		$ 622	32,358,068		(12,659,895)	19,698,795
Beginnig balance, shares at Dec. 31, 2020		6,220,927
Net loss						(8,822,755)
Other comprehensive loss						(102,689)
Ending balance, value at Sep. 30, 2021		$ 1,119	97,312,794	(102,689)	(21,482,650)	75,728,574
Ending balance, shares at Sep. 30, 2021		11,186,999
Beginning balance, value at Mar. 31, 2021		$ 1,118	96,842,698		(15,112,190)	81,731,626
Beginnig balance, shares at Mar. 31, 2021		11,181,447
Common stock issued from warrant and option exercises
Common stock issued from warrant and option exercises, shares		2,592
Stock-based compensation			245,684			245,684
Net loss					(2,316,481)	(2,316,481)
Other comprehensive loss				(47,565)		(47,565)
Ending balance, value at Jun. 30, 2021		$ 1,118	97,088,382	(47,565)	(17,428,671)	79,613,264
Ending balance, shares at Jun. 30, 2021		11,184,039
Common stock issued from warrant and option exercises		$ 1	(1)
Common stock issued from warrant and option exercises, shares		2,960
Stock-based compensation			224,413			224,413
Net loss					(4,053,979)	(4,053,979)
Other comprehensive loss				(55,124)		(55,124)
Ending balance, value at Sep. 30, 2021		$ 1,119	97,312,794	(102,689)	(21,482,650)	75,728,574
Ending balance, shares at Sep. 30, 2021		11,186,999
Beginning balance, value at Dec. 31, 2021		$ 1,109	96,685,924	(92,689)	(25,022,924)	71,571,420
Beginnig balance, shares at Dec. 31, 2021		11,088,835
Common stock issued from warrant and option exercises		$ 10	299,778			299,788
Common stock issued from warrant and option exercises, shares		95,779
Stock-based compensation			267,004			267,004
Net loss					(4,121,774)	(4,121,774)
Other comprehensive loss				(218,780)		(218,780)
Share repurchases		$ (36)	(2,482,250)			(2,482,286)
Share repurchases, shares		(353,667)
Ending balance, value at Mar. 31, 2022		$ 1,083	94,770,456	(311,469)	(29,144,698)	65,315,372
Ending balance, shares at Mar. 31, 2022		10,830,947
Beginning balance, value at Dec. 31, 2021		$ 1,109	96,685,924	(92,689)	(25,022,924)	71,571,420
Beginnig balance, shares at Dec. 31, 2021		11,088,835
Net loss						(10,878,841)
Other comprehensive loss						$ (342,346)
Common stock issued from option exercises, shares		715,782				32,538
Ending balance, value at Sep. 30, 2022		$ 1,086	95,361,099	(435,035)	(35,901,765)	$ 59,025,385
Ending balance, shares at Sep. 30, 2022		10,857,040
Beginning balance, value at Mar. 31, 2022		$ 1,083	94,770,456	(311,469)	(29,144,698)	65,315,372
Beginnig balance, shares at Mar. 31, 2022		10,830,947
Stock-based compensation			289,533			289,533
Net loss					(4,492,386)	(4,492,386)
Other comprehensive loss				(37,012)		(37,012)
Ending balance, value at Jun. 30, 2022		$ 1,083	95,059,989	(348,481)	(33,637,084)	61,075,507
Ending balance, shares at Jun. 30, 2022		10,830,947
Stock-based compensation			301,113			301,113
Net loss					(2,264,681)	(2,264,681)
Other comprehensive loss				(86,554)		(86,554)
Common stock issued from option exercises		$ 3	(3)
Common stock issued from option exercises, shares		26,093
Ending balance, value at Sep. 30, 2022		$ 1,086	$ 95,361,099	$ (435,035)	$ (35,901,765)	$ 59,025,385
Ending balance, shares at Sep. 30, 2022		10,857,040

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (10,878,841)	$ (8,822,755)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	7,321	4,770
Non-cash lease adjustments	108,451	21,553
Stock-based compensation	857,650	715,616
Amortization of investment premium	87,211
Gain on loan forgiveness		(109,223)
Realized loss on foreign currency translation	158,703
Realized loss on sale of marketable securities	76,326
Unrealized loss on investment securities	476,751	14,908
Changes in assets and liabilities:
Prepaid expenses and other current assets	(1,759,848)	(493,647)
Accounts payable and accrued expenses	885,998	134,152
Operating lease liabilities	(118,351)
Other assets		(17,889)
Net cash flows used in operating activities	(10,098,629)	(8,552,515)
INVESTING ACTIVITIES
Purchase of property and equipment	(20,889)	(15,498)
Purchase of marketable securities	(3,322,386)	(19,281,130)
Sale of marketable securities	2,919,682
Net cash flows used in investing activities	(423,593)	(19,296,628)
FINANCING ACTIVITIES
Proceeds from issuance of common and preferred stock		68,999,994
Issuance costs		(4,783,816)
Repurchase of shares including commissions	(2,482,286)
Proceeds from stock option and warrant exercises	299,788	72,753
Net cash flows (used in) / provided by financing activities	(2,182,498)	64,288,931
Effect of foreign exchange rates on cash	(20,508)
CHANGE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH FOR THE PERIOD	(12,725,228)	36,439,788
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD	52,524,295	19,229,232
CASH, CASH EQUIVALENTS AND RESTRICTED CASH	39,799,067	55,669,020
RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS:
Cash and cash equivalents	39,257,887	54,669,020
Restricted cash	541,180	1,000,000
Non-cash investing and financing activities
Application of deferred offering costs to public offering proceeds		(49,324)
Unrealized losses on debt securities	$ (394,843)	$ (102,689)

Organization, Principal Activit

Organization, Principal Activities, and Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Principal Activities, and Basis of Presentation	Note 1. Organization, Principal Activities, and Basis of Presentation Lantern Pharma Inc., and Subsidiaries (the “Company”) is a clinical stage biopharmaceutical company, focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies. The Company’s portfolio of therapies consists of small molecule drug candidates that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that it is developing with the assistance of its A.I. platform and its biomarker driven approach. The Company’s A.I. platform, known as RADR ® Lantern Pharma Inc. was incorporated under the laws of the state of Texas on November 7, 2013, and thereafter reincorporated in the state of Delaware on January 15, 2020. The Company’s principal operations are located in Texas. The Company formed a wholly owned subsidiary, Lantern Pharma Limited, in the United Kingdom in July 2017 and a wholly owned subsidiary, Lantern Pharma Australia Pty Ltd, in Australia in September 2021. Since inception, the Company has devoted substantially all its activity to advancing research and development, including efforts in connection with preclinical studies, clinical trials and development of its RADR platform. This now includes four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eleven disclosed therapeutic targets: ● LP-100 (irofulven) in a phase II trial for the treatment of prostate cancer; ● LP-300 (Tavocept), which we recently launched in a Phase II clinical trial, the Harmonic ™ ● LP-184 in preclinical studies for treatment of solid tumors including pancreatic, prostate, and bladder cancers and glioblastoma; ● LP-284, the stereoisomer (enantiomer) of LP-184, that has shown promising in-vitro ● Our ADC program commenced in early 2021, and is aimed at identifying targeted or therapeutic antibodies to conjugate with selected compounds. The Company’s fiscal year ends on December 31 of each calendar year. The accompanying interim condensed consolidated financial statements are unaudited and have been prepared on the same basis as the Company’s annual consolidated financial statements for the fiscal year ended December 31, 2021. In the opinion of the Company’s management, these interim condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods presented. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from these estimates. The December 31, 2021 year-end condensed consolidated balance sheet data in the accompanying interim condensed consolidated financial statements was derived from audited consolidated financial statements. These condensed consolidated financial statements and notes do not include all disclosures required by U.S. generally accepted accounting principles and should be read in conjunction with the Company’s audited consolidated financial statements as of and for the year ended December 31, 2021 and the notes thereto included in the Company’s Annual Report on Form 10-K, dated March 10, 2022, on file with the Securities and Exchange Commission. The results of operations and cash flows for the interim periods included in these condensed consolidated financial statements are not necessarily indicative of the results to be expected for any future period or the entire fiscal year. Any reference in these notes to applicable guidance refers to Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). To date, the Company has operated its business as one segment. The Company’s condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Lantern Pharma Limited and Lantern Pharma Australia Pty Ltd. All intercompany balances and transactions have been eliminated in consolidation.

Liquidity

Liquidity	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity	Note 2. Liquidity The Company incurred a net loss of approximately $ 10,879,000 8,823,000 58,881,000

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3. Summary of Significant Accounting Policies Use of Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The significant areas of estimation include determining research and development accruals and the inputs in determining the fair value of equity-based awards and warrants issued. Actual results could differ from those estimates. Risks and Uncertainties The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. Operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including the potential risk of business failure. The extent of the impact and effects of the coronavirus (COVID-19) on the operation and financial performance of the Company’s business will depend on future developments, including the duration and spread of the outbreak and varying virus mutations, related travel advisories and restrictions, the recovery time of disrupted research services, the consequential staff shortages, and research and development delays, or the uncertainty with respect to the accessibility of additional liquidity or capital markets, all of which are highly uncertain and cannot be predicted. If the Company’s operations are impacted by the outbreak for an extended period, the Company’s results of operations or liquidity may be materially adversely affected. Research and Development Research and development costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses, costs for manufacturing and supplies, and technical infrastructure on the cloud for the purposes of developing the Company’s RADR platform and identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as the work is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that have no alternative future use are expensed when incurred. Cash and Cash Equivalents The Company considers money market funds with a short-term maturity of less than one year to be cash equivalents. Restricted Cash The Company considers cash held in escrow for the purposes of contractual contingencies to be restricted cash. All of the restricted cash at September 30, 2022 and December 31, 2021, relates to escrow amounts in connection with the Asset Purchase Agreement entered into by the Company and Allarity Therapeutics in July 2021 (See Note 4) and is considered a current asset at September 30, 2022, as the escrow milestones that could require payments to be made to Allarity Therapeutics must be satisfied within the next 12 months. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets as of September 30, 2022 totaled approximately $ 3,652,000 2,304,000 281,000 762,000 305,000 Leases The Company determines whether an arrangement contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liabilities, and net of current portion of operating lease liabilities on our consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As the Company’s leases do not provide an implicit rate, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments. The Company does not include options to extend or terminate the lease term unless it is reasonably certain that the Company will exercise any such options. Rent expense is recognized under the operating leases on a straight-line basis. The Company does not recognize right-of-use assets or lease liabilities for short-term leases, which have a lease term of twelve months or less, and instead will recognize lease payments as expense on a straight-line basis over the lease term. Marketable Securities The Company’s marketable securities consist of government and agency securities, corporate bonds, and mutual funds. We classify our marketable securities as available-for-sale at the time of purchase and reevaluate such classification as of each balance sheet date. We may sell these securities at any time for use in current operations even if they have not yet reached maturity. As a result, we classify our investments, including securities with maturities beyond twelve months as current assets in the accompanying consolidated balance sheets. Available-for-sale debt securities are recorded at fair value each reporting period. Unrealized gains and losses are excluded from earnings and recorded as a separate component within accumulated other comprehensive income on the consolidated balance sheets until realized. Interest is reported within interest income and dividend income is reported within other income, net on the consolidated statements of operations. We evaluate our investments to assess whether the amortized cost basis is in excess of estimated fair value and determine what amount of that difference, if any, is caused by expected credit losses. Allowance for credit losses are recognized as a charge in other (expense) income, net on the consolidated statements of operations, and any remaining unrealized losses are included in accumulated other comprehensive loss on the consolidated balance sheets. There were no credit losses recorded for the three and nine months ended September 30, 2022 and 2021. There was no impairment charge for any unrealized losses for the three and nine months ended September 30, 2022 and 2021. We determine realized gains and losses on the sale of marketable securities based on the specific identification method and record such gains and losses in other (expense) income, net on the consolidated statements of operations. New Accounting Pronouncements, Not Yet Adopted Current Expected Credit Loss In June 2016 the FASB issued Accounting Standard Update (ASU) 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326). This introduces new methodology for recognition of credit losses - the current expected credit loss (“CECL”) method. The CECL method requires the recognition of all losses expected over the life of a financial instrument upon origination or purchase of the instrument, unless the company elects to recognize such instruments at fair value with changes in profit and loss. CECL is effective for the Company on January 1, 2023. The Company does not anticipate a material impact from the adoption of this new standard on its financial statements.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 4. Commitments and Contingencies General The Company has entered into, and expects to enter into from time to time in the future, license agreements, strategic alliance agreements, assignment agreements, research service agreements, and similar agreements related to the advancement of its product candidates and research and development efforts. Significant agreements are described in detail below (collectively, the “License, Strategic Alliance, and Research Agreements”). Set forth below are the approximate amounts expensed for License, Strategic Alliance, and Research Agreements during the three and nine months ended September 30, 2022 and September 30, 2021, respectively. These expensed amounts are included under research and development expenses in the accompanying condensed consolidated statements of operations. Schedule Of Research And Development 2022 2021 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Amount Expensed for License, Strategic Alliance, and Research Agreements $ (25,000 )* $ 2,077,000 $ 3,764,000 * $ 3,200,000 * Amounts expensed for License, Strategic Alliance, and Research Agreements during the three and nine months ended September 30, 2022 were reduced by $ 935,000 Set forth below at September 30, 2022 and December 31, 2021, respectively, are (1) the approximate amounts accrued and payable under the License, Strategic Alliance, and Research Agreements, and (2) the approximate amount of prepaid expenses and other current assets under the License, Strategic Alliance, and Research Agreements. These amounts are included in the accompanying condensed consolidated balance sheets. Schedule of Accounts Payable And Accrued Liabilities September 30, December 31, Amount accrued and payable under License, Strategic Alliance, and Research Agreements $ 2,061,000 $ 1,493,000 Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements $ 2,286,000 $ 1,023,000 BioNumerik Pharmaceuticals In January 2018, the Company entered into an Assignment Agreement (the “Assignment Agreement”) with BioNumerik Pharmaceuticals, Inc. (“BioNumerik”), pursuant to which the Company acquired rights to domestic and international patents, trademarks and related technology and data relating to LP-300 (Tavocept) for human therapeutic treatment indications. The Assignment Agreement replaced a License Agreement that was entered into between the Company and BioNumerik in May 2016. The Company made upfront payments totaling $ 25,000 In the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100 million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative revenue in excess of $1 billion If the Company enters into a third-party transaction for LP-300, the Company is required to pay the BioNumerik-related payment recipients a specified percentage of any upfront, milestone, and royalty amounts received by the Company from the transaction, after first recovering specified direct costs incurred by the Company for the development of LP-300 that are not otherwise reimbursed from such third-party transaction. In addition, the Assignment Agreement provides that the Company will use commercially diligent efforts to develop LP-300 and make specified regulatory filings and pay specified development and regulatory costs related to LP-300. The Assignment Agreement also provides that the Company will provide TriviumVet DAC (“TriviumVet”) with (i) specified data and information generated by the Company with respect to LP-300, and (ii) an exclusive license to use specified LP-300-related patent rights, trademark rights and related intellectual property to support LP-300 development in non-human (animal) treatment indications. The Company is also required to pay all patent costs on covered patents related to LP-300. These patent costs are included in general and administrative expenses in the accompanying condensed consolidated statements of operations. These patent costs are fully recoverable at the time of any net revenue from LP-300, with up to 50 In addition to the recovery of patent costs, the Company has the right to recover the $ 25,000 AF Chemicals In January 2015, the Company entered into a Technology License Agreement to exclusively license domestic and international patent rights from AF Chemicals, LLC (“AF Chemicals”) for the treatment of cancer in humans for the compounds LP-100 (Irofulven) and LP-184. In February 2016, the Company and AF Chemicals entered into an Addendum (the “Addendum”) providing for additions and amendments to the Technology License Agreement. In December 2020, the Company and AF Chemicals entered into a Second Addendum (the “Second Addendum”) providing for further additions and amendments to the Technology License Agreement. The Technology License Agreement, Addendum and Second Addendum are collectively referred to as the “AFC License Agreement”. Pursuant to the Second Addendum, the Company made specified payments to AF Chemicals during the nine months ended September 30, 2021. The Second Addendum also provides that, from December 30, 2020 until January 15, 2025, the Company will have no obligation to pay annual licensing fees, development diligence extension payments, or patent maintenance fee payments to AFC under the AFC License Agreement. As part of the Second Addendum, the Company has agreed to apply for specified orphan drug designations for LP-184 in the US and EU. The Second Addendum also amends and clarifies other provisions of the Technology License Agreement, and provides the Company with the ability to recover a portion of initial payments made under the Second Addendum from sublicense fees or royalty payments that may be made to AFC by the Company or third parties prior to January 15, 2025. Pursuant to the AFC License Agreement the Company made annual licensing fee payments to AF Chemicals relating to LP-184 for periods prior to signing the Second Addendum. In addition, the Company is obligated to make milestone payments to AF Chemicals at the time of an Investigational New Drug Application (“IND”) filing relating to LP-184 and also upon reaching additional specified milestones in connection with the development and potential marketing approval of LP-184 in the United States, specified countries in Europe, and other countries. The AFC License Agreement also provides that the Company will pay AF Chemicals a royalty of at least a very small single digit percentage of specified net sales of LP-184 and other analogs. In addition, the AFC License Agreement contains specified time requirements for the Company to file an IND, enroll patients in clinical trials, and file a potential NDA with respect to LP-184, with the ability for the Company to pay AF Chemicals additional amounts ranging up to an amount in the low hundreds of thousands of dollars for each one, two, three and four year extension to such development time requirements, with additional extensions beyond four years to be negotiated by the Company and AF Chemicals Pursuant to the Second Addendum, no additional payments of annual licensing fees or development diligence extension payments related to LP-184 are required to be made by the Company until January 15, 2025, at which time these obligations will resume. The Company will also be obligated to make payments to AF Chemicals relating to LP-100 beginning January 15, 2025, as described below. In the event of a sublicense of the LP-184 rights, the Company is obligated to pay AF Chemicals (a) a low double-digit percentage of the gross income and fees received by the Company with respect to the United States in connection with such sublicense, and (b) a lower double digit percentage of the gross income and fees received by the Company with respect to Europe and Japan in connection with such sublicense. The amounts to be paid to AF Chemicals with respect to LP-100 under the AFC License Agreement are in many ways similar to the amounts to be paid with respect to LP-184 as described above. In addition, the AFC License Agreement contains specified time requirements for the Company to enroll patients in clinical trials and file a potential NDA with respect to LP-100. Extension fees may be paid by the Company to AF Chemicals from time to time related to these requirements. Pursuant to the Second Addendum with AF Chemicals, no additional payments of annual licensing fees or development diligence extension payments are required to be made by the Company with respect to LP-100 until January 15, 2025, at which time these obligations will resume. Allarity Therapeutics (formerly known as Oncology Venture) In May 2015, the Company licensed various rights to LP-100 to Oncology Venture (now known as Allarity Therapeutics) pursuant to a Drug License and Development Agreement. In February 2016, the Company and Allarity Therapeutics entered into an addendum and an amendment providing for additions and amendments to the Drug License and Development Agreement. In connection with the Drug License and Development Agreement, as amended (collectively, the “Allarity License and Development Agreement”), Allarity Therapeutics agreed to directly pay to AF Chemicals on behalf of the Company certain amounts to satisfy the Company’s milestone obligations to AF Chemicals with respect to LP-100 under the AFC License Agreement. Amounts paid by Allarity Therapeutics to AF Chemicals on behalf of the Company would then be deducted from amounts owed by Allarity Therapeutics to the Company. On July 23, 2021, the Company entered into an Asset Purchase Agreement to reacquire global development and commercialization rights for Irofulven (LP-100) from Allarity. The transaction includes global rights to LP-100, as well as the developed clinical protocol for an intended study in bladder and prostate cancer patients who have a mutation in the ERCC2/3 genes. As a result of this transaction, the Company has full authority to manage and guide future clinical development and commercialization of LP-100. Under the terms of the Asset Purchase Agreement, the Company paid an initial upfront payment of $ 1,000,000 459,000 500,000 Califia Pharma In December 2020, the Company entered into an Evaluation and Limited Use Agreement (the “Evaluation Agreement”) with Califia Pharma, Inc. (“Califia”). The Evaluation Agreement provided for the Company and Califia to collaborate on the in vitro and in vivo testing and evaluation of novel Califia linker technology and related payloads to be conjugated to a Lantern targeting entity. The Evaluation Agreement also provided the Company with the right to negotiate with Califia for exclusive license rights to use LP-184 and related analogs as the payload with an affinity drug conjugate or small molecule drug conjugate targeting entity supplied by the Company. The Company also had the right under the Evaluation Agreement to negotiate for non-exclusive license rights to use a targeting entity from the Company with a payload and linker combination selected from novel specified Califia payloads and linkers. The Evaluation Agreement expired on December 31, 2021 and the Company determined not to extend it. Patheon API Services The Company has entered into agreements with Patheon API Services, Inc. (“Patheon”) for the manufacture and supply of cGMP material to support the Company’s Phase II clinical trial for its product candidate LP-300. In addition to producing LP-300 API (active pharmaceutical ingredient) under cGMP (current Good Manufacturing Practices) conditions, Patheon transferred previously validated manufacturing processes and analytical methods for LP-300 and produced non-GMP material for use in support of non-clinical studies for LP-300. The agreements provide for payments in stages as specified process and manufacturing milestones are achieved. Patheon, a part of Thermo Fisher Scientific, has previously developed and/or manufactured more than 700 pharmaceuticals for biopharma clients and has more than 55 locations around the world, providing access to a fully integrated global network of facilities. The Company expects to pay additional amounts to Patheon in future periods in accordance with specified process and manufacturing milestones under the Patheon agreements. Southwest Research Institute As part of the Company’s research and development activities, the Company has engaged Southwest Research Institute (“SwRI”) from time to time to assist with compound synthesis and manufacturing related activities for the Company’s product candidates. The Company has entered into agreements with SwRI for the non-GMP and cGMP synthesis of LP-184 material and related analytical development. The Company expects to pay additional amounts to SwRI in future periods as additional work is conducted by SwRI under the agreements. The Research Institute of Fox Chase Cancer Center In September 2020, the Company entered into a research agreement with the Research Institute of Fox Chase Cancer Center (“FCCC”), which was amended in January 2022, as part of the Company’s research and development activities, with a focus on advancing the targeted use of LP-184 in molecularly-defined sub-types of pancreatic cancer. Piramal Pharma Solutions In January 2021, the Company entered into an agreement with Piramal Pharma Solutions (“Piramal”) for the fill and finish manufacture of LP-300 drug product at Piramal’s Lexington, Kentucky site in support of future Phase II clinical testing. The agreement, as amended, provides for Piramal to conduct activities in support of the cGMP manufacturing of LP-300, including analytical and process transfer activities, manufacture of cGMP clinical batches, and performance of stability studies on cGMP batches of LP-300 drug product. The Company expects to pay additional amounts to Piramal in future periods in accordance with the payment schedule specified under the Piramal agreement. vivoPharm In September 2021, the Company’s Australian subsidiary entered into an agreement with RDDT, a vivoPharm Company Pty Ltd (“vivoPharm”), for multiple preclinical studies, including animal studies, as part of an IND-enabling program for LP-184. The Company’s Australian subsidiary entered into an additional agreement with vivoPharm in June 2022 as part of an IND-enabling program for LP-284. The Company expects that additional amounts will be paid to vivoPharm in future periods in accordance with the payment schedule specified under the vivoPharm agreements, as amended. TD2 In October 2021, the Company entered into a Statement of Work, as amended in March 2022, with Translational Drug Development, LLC (“TD2”) providing for TD2 to serve as the lead contract research organization (CRO) for the Company’s Phase II clinical trial for its product candidate LP-300. The Company expects to make payments over the next 18 to 24 months in connection with services provided by TD2 as well as clinical trial site and other pass-through costs relating to the LP-300 Phase II clinical trial. Berkshire Sterile Manufacturing During the nine months ended September 30, 2022, the Company entered into agreements with Berkshire Sterile Manufacturing (“Berkshire”) to support technical transfer and GMP drug product manufacturing of LP-300. The Company expects that additional amounts will be paid to Berkshire in future periods in accordance with the payment schedule specified under the Berkshire agreements. Shilpa In March 2022, the Company entered into an agreement with Shilpa Medicare Limited (“Shilpa”) for fit-to-purpose process development and synthesis of a key starting material relating to the synthesis of LP-184 under cGMP. In July 2022, the Company entered into agreements with Shilpa Pharma Lifesciences for the cGMP synthesis of LP-184 API material as well as for drug product development and cGMP drug product manufacturing of LP-184. In August 2022, for the cGMP synthesis of LP-284 API material as well as for drug product development and cGMP drug product manufacturing of LP-284. The Company expects that additional amounts will be paid to the Shilpa entities in future periods in accordance with the payment schedule specified under the Shilpa agreements. Curia In June 2022, the Company entered into an agreement with Curia Global, Inc. (“Curia”) for the cGMP manufacture of LP-300 API. The Company expects that additional amounts will be paid to Curia in future periods in accordance with the payment schedule specified under the Curia agreement. Cancer Insight In May 2022, the Company entered into an agreement with Cancer Insight, LLC (“Cancer Insight”) for IND filing, regulatory support, Phase I pre-trial startup activities, and strategic program consulting relating to LP-184. The Company expects that additional amounts will be paid to Cancer Insight in future periods in accordance with the payment schedule specified under the Cancer Insight agreement. Other Research and Service Provider Agreements In addition to the agreements described above, the Company has entered into other research and service provider agreements for the advancement of its product candidates and research and development efforts. The Company expects to pay additional amounts in future periods in connection with existing and future research and service provider agreements. EU Grant In September 2018, Lantern Pharma Limited, a wholly owned subsidiary of Lantern Pharma Inc., was awarded a grant by the UK government in the form of state aid under the Commission Regulations (EU) No. 651/2014 of 17 June 2014 (the “General Block Exemption”), Article 25 Aid for research and development projects, state aid notification no. SA.40154. The grant was awarded to conduct research and development activities for the prostate cancer biomarker analysis of the LP-184 drug candidate. Following the Company’s research and development activities in Northern Ireland, the grant will reimburse the Company 50 24,215 No Actuate Therapeutics In May 2021, the Company entered into a Collaboration Agreement with Actuate Therapeutics, Inc. (“Actuate”), a clinical stage private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis. Pursuant to the agreement, the Company and Actuate are collaborating on utilization of the Company’s RADR® platform to develop novel biomarker derived signatures for use with one of Actuate’s product candidates. As part of the collaboration, the Company received 25,000 The restricted shares of Actuate stock had a nominal value when acquired and, therefore, were recorded at a cost of $ 0

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases
Leases	Note 5. Leases The operating lease cost recognized in general and administrative expenses in our consolidated statements of operations was approximately $ 30,000 108,000 38,000 67,000 The following provides balance sheet information related to leases as of September 30, 2022 and December 31, 2021: Schedule of Balance Sheet Information Related to Leases September 30, December 31, Assets Operating lease, right-of-use asset, net $ 82,918 $ 185,943 Liabilities Current portion of operating lease liabilities $ 92,023 $ 152,058 Operating lease liabilities, net of current portion - 52,890 Total operating lease liabilities $ 92,023 $ 204,948 At September 30, 2022, the future estimated minimum lease payments under non-cancelable operating leases are as follows: Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases 2022 (remaining three months) $ 40,052 2023 53,403 Total minimum lease payments 93,455 Less amount representing interest (1,432 ) Present value of future minimum lease payments 92,023 Less current portion of operating lease liabilities 92,023 Operating lease liabilities, net of current portion $ - In April 2021, we entered into two operating leases for office space that commenced in May 2021. The leases expire in April 2023 Other supplemental information related to operating leases is as follows: Schedule of Other Supplemental Information Related to Operating Leases As of September 30, 2022 2021 Weighted average remaining term of operating leases (in years) 0.58 1.58 Weighted average discount rate of operating leases 4.65 % 4.65 % The Company also leased office space in Dallas, Texas under month-to-month lease arrangements during the three and nine months ended September 30, 2022. Under these short-term leases, the Company elected the short-term lease measurement and recognition exemption under ASC 842 and recorded rent expense as incurred.

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders’ Equity	Note 6. Stockholders’ Equity Common Stock On January 20, 2021, the Company closed a public offering of 4,928,571 14.00 642,856 69,000,000 64,167,000 4,554,000 279,000 101,000 During the three and nine months ended September 30, 2021, the Company issued zero 11,782 1.03 12,000 During the three and nine months ended September 30, 2021, the Company issued zero 19,367 61,000 2,960 6,352 3,832 8,047 3.13 In November 2021, the Company’s Board of Directors authorized a share repurchase program to acquire up to $ 7,000,000 zero 353,667 2,482,000 During the three and nine months ended September 30, 2022, the Company issued 26,093 32,538 During the three and nine months ended September 30, 2022, the Company issued zero 95,779 300,000 3.13 As of September 30, 2022 and December 31, 2021, the Company had 25,000,000 10,857,040 11,088,835 Warrants During the three and nine months ended September 30, 2021, the Company issued zero 19,367 2,960 6,352 3,832 8,047 During the three and nine months ended September 30, 2022, the Company issued zero 95,779 respectively, The Company had warrants to purchase 177,998 9.27 March 7, 2024 June 10, 2025 The Company had warrants to purchase 273,777 7.12 March 17, 2022 June 10, 2025 Options The Company recorded stock-based compensation of approximately $ 301,000 858,000 224,000 716,000 A summary of stock option activity under the Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended and restated (the “Plan”) during the nine months ended September 30, 2022 is presented below: Schedule of Stock Option Activity Options Outstanding Number of Weighted- Outstanding December 31, 2021 890,826 $ 6.54 Granted 155,000 5.79 Exercised (32,538 ) 1.03 Cancelled or expired (12,335 ) 13.79 Outstanding September 30, 2022 1,000,953 $ 6.52 Options were exercisable for 715,782 5.59 In August 2022, the Company granted options relating to 100,000 5.60 15.00 During the nine months ended September 30, 2021, no 11,782 22,238

Marketable Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2022
Cash and Cash Equivalents [Abstract]
Marketable Securities	Note 7. Marketable Securities At September 30, 2022, marketable securities consisted of the following: Schedule of Marketable Securities Amortized Unrealized Unrealized Aggregate Government & Agency Securities $ 5,410,239 $ 77 $ (208,545 ) 5,201,771 Corporate Bonds 8,177,653 - (279,249 ) 7,898,404 Marketable Securities - Debt $ 13,587,892 $ 77 $ (487,794 ) $ 13,100,175 Mutual Funds – Fixed Income 4,002,704 - (334,004 ) 3,668,700 Mutual Funds – Alternative Investments 2,023,154 - (223,304 ) 1,799,850 Marketable Securities – Mutual Funds $ 6,025,858 $ - $ (557,308 ) $ 5,468,550 The contractual maturities of the investments classified as Government & Agency Securities and Corporate Bonds are as follows: Schedule of Contractual Maturities Investments of Marketable Securities As of Due within one year $ 4,669,099 Due in one to two years 6,700,963 Due in two to five years 1,730,113 Total $ 13,100,175 The following table presents gross unrealized losses and fair values for those marketable securities that were in an unrealized loss position as of September 30, 2022, aggregated by investment category and the length of time that individual securities have been in a continuous loss position: Schedule of Gross Unrealized Losses and Fair Values for Marketable Securities As of September 30, Less than 12 months More than 12 months Fair Value Unrealized Loss Fair Value Unrealized Loss Government & Agency Securities $ 1,455,466 $ (54,070 ) $ 3,001,090 $ (154,475 ) Corporate Bonds 1,330,714 (34,791 ) 6,567,690 (244,458 ) Mutual Funds - Fixed Income 1,836,000 (170,004 ) 1,832,700 (164,000 ) Mutual Funds - Alternative Investments - - 1,799,850 (223,304 ) $ 4,622,180 $ (258,865 ) $ 13,201,330 $ (786,237 ) We do not believe the unrealized losses described above represent credit losses based on our evaluation of available evidence as of September 30, 2022, which includes an assessment of whether it is more likely than not we will be required to sell the investment before recovery of the investment’s amortized cost basis. During the three and nine months ended September 30, 2022, bonds were redeemed for approximately $ 900,000 2,570,000 27,000 76,000 350,000

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 8. Fair Value Measurements We determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 - Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 - Inputs are unobservable inputs based on our assumptions. Financial Assets When available, our marketable securities are valued using quoted prices for identical instruments in active markets. If we are unable to value our marketable securities using quoted prices for identical instruments in active markets, we value our investments using broker reports that utilize quoted market prices for comparable instruments. As of September 30, 2022, our available-for-sale debt securities were valued through use of quoted prices for comparable instruments in active markets and are classified as Level 2, and our mutual funds – alternative investments were valued using NAV, net asset value per share, under the practical expedient methodology. Based on our valuation of our marketable securities, we concluded that they are classified in either Level 2 or NAV, and we have no financial assets measured using Level 1 or 3 inputs. The following table presents information about our assets that are measured at fair value on a recurring basis using the above input categories. Schedule of Assets are Measured at Fair Value On a Recurring Basis - Fair Value Measurements as of September 30, Description Total Level 1 Level 2 Level 3 NAV* Government & Agency Securities $ 5,201,771 $ - $ 5,201,771 $ - $ - Corporate Bonds 7,898,404 - 7,898,404 - - Mutual Funds – Fixed Income 3,668,700 - 3,668,700 - - Mutual Funds – Alternative Investments 1,799,850 - - - 1,799,850 Fair value recurring basis $ 18,568,725 $ - $ 16,768,875 $ - $ 1,799,850 * Certain marketable securities investments are measured at fair value using net asset value per share under the practical expedient methodology.

Notes and Loan Payable

Notes and Loan Payable	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Notes and Loan Payable	Note 9. Notes and Loan Payable On May 1, 2020 (the “Origination Date”), the Company received $ 108,500 the PPP Loan bore interest at a fixed rate of one percent ( 1.0

Loss Per Share of Common Shares

Loss Per Share of Common Shares	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Loss Per Share of Common Shares	Note 10. Loss Per Share of Common Shares Basic loss per share is derived by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants and stock options, which would result in the issuance of incremental shares of common stock unless such effect is anti-dilutive. In calculating the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remained the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation. Potentially dilutive securities outstanding that have been excluded from diluted loss per share due to being anti-dilutive include the following: Schedule of Anti-dilutive Securities Outstanding Diluted Loss Per Share Outstanding at 2022 2021 Warrants to purchase Common Stock 177,998 298,204 Stock options 1,000,953 801,588 Total 1,178,951 1,099,792

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Use of Estimates and Assumptions	Use of Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The significant areas of estimation include determining research and development accruals and the inputs in determining the fair value of equity-based awards and warrants issued. Actual results could differ from those estimates.
Risks and Uncertainties	Risks and Uncertainties The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. Operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including the potential risk of business failure. The extent of the impact and effects of the coronavirus (COVID-19) on the operation and financial performance of the Company’s business will depend on future developments, including the duration and spread of the outbreak and varying virus mutations, related travel advisories and restrictions, the recovery time of disrupted research services, the consequential staff shortages, and research and development delays, or the uncertainty with respect to the accessibility of additional liquidity or capital markets, all of which are highly uncertain and cannot be predicted. If the Company’s operations are impacted by the outbreak for an extended period, the Company’s results of operations or liquidity may be materially adversely affected.
Research and Development	Research and Development Research and development costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses, costs for manufacturing and supplies, and technical infrastructure on the cloud for the purposes of developing the Company’s RADR platform and identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as the work is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that have no alternative future use are expensed when incurred.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers money market funds with a short-term maturity of less than one year to be cash equivalents.
Restricted Cash	Restricted Cash The Company considers cash held in escrow for the purposes of contractual contingencies to be restricted cash. All of the restricted cash at September 30, 2022 and December 31, 2021, relates to escrow amounts in connection with the Asset Purchase Agreement entered into by the Company and Allarity Therapeutics in July 2021 (See Note 4) and is considered a current asset at September 30, 2022, as the escrow milestones that could require payments to be made to Allarity Therapeutics must be satisfied within the next 12 months.
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets as of September 30, 2022 totaled approximately $ 3,652,000 2,304,000 281,000 762,000 305,000
Leases	Leases The Company determines whether an arrangement contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liabilities, and net of current portion of operating lease liabilities on our consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As the Company’s leases do not provide an implicit rate, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments. The Company does not include options to extend or terminate the lease term unless it is reasonably certain that the Company will exercise any such options. Rent expense is recognized under the operating leases on a straight-line basis. The Company does not recognize right-of-use assets or lease liabilities for short-term leases, which have a lease term of twelve months or less, and instead will recognize lease payments as expense on a straight-line basis over the lease term.
Marketable Securities	Marketable Securities The Company’s marketable securities consist of government and agency securities, corporate bonds, and mutual funds. We classify our marketable securities as available-for-sale at the time of purchase and reevaluate such classification as of each balance sheet date. We may sell these securities at any time for use in current operations even if they have not yet reached maturity. As a result, we classify our investments, including securities with maturities beyond twelve months as current assets in the accompanying consolidated balance sheets. Available-for-sale debt securities are recorded at fair value each reporting period. Unrealized gains and losses are excluded from earnings and recorded as a separate component within accumulated other comprehensive income on the consolidated balance sheets until realized. Interest is reported within interest income and dividend income is reported within other income, net on the consolidated statements of operations. We evaluate our investments to assess whether the amortized cost basis is in excess of estimated fair value and determine what amount of that difference, if any, is caused by expected credit losses. Allowance for credit losses are recognized as a charge in other (expense) income, net on the consolidated statements of operations, and any remaining unrealized losses are included in accumulated other comprehensive loss on the consolidated balance sheets. There were no credit losses recorded for the three and nine months ended September 30, 2022 and 2021. There was no impairment charge for any unrealized losses for the three and nine months ended September 30, 2022 and 2021. We determine realized gains and losses on the sale of marketable securities based on the specific identification method and record such gains and losses in other (expense) income, net on the consolidated statements of operations.
New Accounting Pronouncements, Not Yet Adopted	New Accounting Pronouncements, Not Yet Adopted Current Expected Credit Loss In June 2016 the FASB issued Accounting Standard Update (ASU) 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326). This introduces new methodology for recognition of credit losses - the current expected credit loss (“CECL”) method. The CECL method requires the recognition of all losses expected over the life of a financial instrument upon origination or purchase of the instrument, unless the company elects to recognize such instruments at fair value with changes in profit and loss. CECL is effective for the Company on January 1, 2023. The Company does not anticipate a material impact from the adoption of this new standard on its financial statements.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule Of Research And Development	Set forth below are the approximate amounts expensed for License, Strategic Alliance, and Research Agreements during the three and nine months ended September 30, 2022 and September 30, 2021, respectively. These expensed amounts are included under research and development expenses in the accompanying condensed consolidated statements of operations. Schedule Of Research And Development 2022 2021 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Amount Expensed for License, Strategic Alliance, and Research Agreements $ (25,000 )* $ 2,077,000 $ 3,764,000 * $ 3,200,000 * Amounts expensed for License, Strategic Alliance, and Research Agreements during the three and nine months ended September 30, 2022 were reduced by $ 935,000
Schedule of Accounts Payable And Accrued Liabilities	Set forth below at September 30, 2022 and December 31, 2021, respectively, are (1) the approximate amounts accrued and payable under the License, Strategic Alliance, and Research Agreements, and (2) the approximate amount of prepaid expenses and other current assets under the License, Strategic Alliance, and Research Agreements. These amounts are included in the accompanying condensed consolidated balance sheets. Schedule of Accounts Payable And Accrued Liabilities September 30, December 31, Amount accrued and payable under License, Strategic Alliance, and Research Agreements $ 2,061,000 $ 1,493,000 Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements $ 2,286,000 $ 1,023,000

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases
Schedule of Balance Sheet Information Related to Leases	The following provides balance sheet information related to leases as of September 30, 2022 and December 31, 2021: Schedule of Balance Sheet Information Related to Leases September 30, December 31, Assets Operating lease, right-of-use asset, net $ 82,918 $ 185,943 Liabilities Current portion of operating lease liabilities $ 92,023 $ 152,058 Operating lease liabilities, net of current portion - 52,890 Total operating lease liabilities $ 92,023 $ 204,948
Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases	At September 30, 2022, the future estimated minimum lease payments under non-cancelable operating leases are as follows: Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases 2022 (remaining three months) $ 40,052 2023 53,403 Total minimum lease payments 93,455 Less amount representing interest (1,432 ) Present value of future minimum lease payments 92,023 Less current portion of operating lease liabilities 92,023 Operating lease liabilities, net of current portion $ -
Schedule of Other Supplemental Information Related to Operating Leases	Other supplemental information related to operating leases is as follows: Schedule of Other Supplemental Information Related to Operating Leases As of September 30, 2022 2021 Weighted average remaining term of operating leases (in years) 0.58 1.58 Weighted average discount rate of operating leases 4.65 % 4.65 %

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Schedule of Stock Option Activity	A summary of stock option activity under the Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended and restated (the “Plan”) during the nine months ended September 30, 2022 is presented below: Schedule of Stock Option Activity Options Outstanding Number of Weighted- Outstanding December 31, 2021 890,826 $ 6.54 Granted 155,000 5.79 Exercised (32,538 ) 1.03 Cancelled or expired (12,335 ) 13.79 Outstanding September 30, 2022 1,000,953 $ 6.52

Marketable Securities (Tables)

Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2022
Cash and Cash Equivalents [Abstract]
Schedule of Contractual Maturities Investments of Marketable Securities	At September 30, 2022, marketable securities consisted of the following: Schedule of Marketable Securities Amortized Unrealized Unrealized Aggregate Government & Agency Securities $ 5,410,239 $ 77 $ (208,545 ) 5,201,771 Corporate Bonds 8,177,653 - (279,249 ) 7,898,404 Marketable Securities - Debt $ 13,587,892 $ 77 $ (487,794 ) $ 13,100,175 Mutual Funds – Fixed Income 4,002,704 - (334,004 ) 3,668,700 Mutual Funds – Alternative Investments 2,023,154 - (223,304 ) 1,799,850 Marketable Securities – Mutual Funds $ 6,025,858 $ - $ (557,308 ) $ 5,468,550 The contractual maturities of the investments classified as Government & Agency Securities and Corporate Bonds are as follows: Schedule of Contractual Maturities Investments of Marketable Securities As of Due within one year $ 4,669,099 Due in one to two years 6,700,963 Due in two to five years 1,730,113 Total $ 13,100,175
Schedule of Contractual Maturities Investments of Marketable Securities	The contractual maturities of the investments classified as Government & Agency Securities and Corporate Bonds are as follows: Schedule of Contractual Maturities Investments of Marketable Securities As of Due within one year $ 4,669,099 Due in one to two years 6,700,963 Due in two to five years 1,730,113 Total $ 13,100,175
Schedule of Gross Unrealized Losses and Fair Values for Marketable Securities	The following table presents gross unrealized losses and fair values for those marketable securities that were in an unrealized loss position as of September 30, 2022, aggregated by investment category and the length of time that individual securities have been in a continuous loss position: Schedule of Gross Unrealized Losses and Fair Values for Marketable Securities As of September 30, Less than 12 months More than 12 months Fair Value Unrealized Loss Fair Value Unrealized Loss Government & Agency Securities $ 1,455,466 $ (54,070 ) $ 3,001,090 $ (154,475 ) Corporate Bonds 1,330,714 (34,791 ) 6,567,690 (244,458 ) Mutual Funds - Fixed Income 1,836,000 (170,004 ) 1,832,700 (164,000 ) Mutual Funds - Alternative Investments - - 1,799,850 (223,304 ) $ 4,622,180 $ (258,865 ) $ 13,201,330 $ (786,237 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Assets are Measured at Fair Value On a Recurring Basis	Schedule of Assets are Measured at Fair Value On a Recurring Basis - Fair Value Measurements as of September 30, Description Total Level 1 Level 2 Level 3 NAV* Government & Agency Securities $ 5,201,771 $ - $ 5,201,771 $ - $ - Corporate Bonds 7,898,404 - 7,898,404 - - Mutual Funds – Fixed Income 3,668,700 - 3,668,700 - - Mutual Funds – Alternative Investments 1,799,850 - - - 1,799,850 Fair value recurring basis $ 18,568,725 $ - $ 16,768,875 $ - $ 1,799,850 * Certain marketable securities investments are measured at fair value using net asset value per share under the practical expedient methodology.

Loss Per Share of Common Shar_2

Loss Per Share of Common Shares (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of Anti-dilutive Securities Outstanding Diluted Loss Per Share	Schedule of Anti-dilutive Securities Outstanding Diluted Loss Per Share Outstanding at 2022 2021 Warrants to purchase Common Stock 177,998 298,204 Stock options 1,000,953 801,588 Total 1,178,951 1,099,792

Liquidity (Details Narrative)

Liquidity (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 2,264,681	$ 4,492,386	$ 4,121,774	$ 4,053,979	$ 2,316,481	$ 2,452,295	$ 10,878,841	$ 8,822,755
Working capital	$ 58,881,000						$ 58,881,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Prepaid expense and other current assets	$ 3,651,968	$ 1,990,953
Upfront payments for contractor fees, academic research studies and services, and subscriptions	2,304,000
Intellectual property related licensing and other fees	281,000
Prepaid annual insurance fees	762,000
Interest receivable	$ 305,000

Schedule Of Research And Develo

Schedule Of Research And Development (Details) - License Strategic Alliance And Research Agreements [Member] - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2022		Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amount Expensed for License, Strategic Alliance, and Research Agreements	$ (25,000)	[1]	$ 2,077,000	$ 3,764,000	$ 3,200,000
Research and development expense	$ 935,000			$ 935,000
[1]Amounts expensed for License, Strategic Alliance, and Research Agreements during the three and nine months ended September 30, 2022 were reduced by $ 935,000

Schedule Of Research And Deve_2

Schedule Of Research And Development (Details) (Parenthetical) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
License Strategic Alliance And Research Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense	$ 935,000	$ 935,000

Schedule of Accounts Payable An

Schedule of Accounts Payable And Accrued Liabilities (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements	$ 3,651,968	$ 1,990,953
License Strategic Alliance And Research Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amount accrued and payable under License, Strategic Alliance, and Research Agreements	2,061,000	1,493,000
Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements	$ 2,286,000	$ 1,023,000

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)		1 Months Ended		3 Months Ended		9 Months Ended
	Jul. 23, 2021 USD ($)	May 31, 2021 USD ($) shares	Jan. 31, 2018 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 GBP (£)	Sep. 30, 2021 USD ($)
Research and development expense				$ 702,296	$ 2,964,391	$ 6,351,356		$ 5,408,320
Assignment Agreement [Member]
Upfront payments						$ 25,000
Revenue percentage						50%	50%
Bio Numerik Pharmaceuticals [Member] | Assignment Agreement [Member]
Upfront payments			$ 25,000
Commitments description			In the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100 million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative revenue in excess of $1 billion
AF Chemicals [Member] | AFC License Agreement [Member]
License agreement, description						In addition, the AFC License Agreement contains specified time requirements for the Company to file an IND, enroll patients in clinical trials, and file a potential NDA with respect to LP-184, with the ability for the Company to pay AF Chemicals additional amounts ranging up to an amount in the low hundreds of thousands of dollars for each one, two, three and four year extension to such development time requirements, with additional extensions beyond four years to be negotiated by the Company and AF Chemicals	In addition, the AFC License Agreement contains specified time requirements for the Company to file an IND, enroll patients in clinical trials, and file a potential NDA with respect to LP-184, with the ability for the Company to pay AF Chemicals additional amounts ranging up to an amount in the low hundreds of thousands of dollars for each one, two, three and four year extension to such development time requirements, with additional extensions beyond four years to be negotiated by the Company and AF Chemicals
Allarity Therapeuties [Member] | Asset Purchase Agreement [Member]
Upfront payments	$ 1,000,000
Escrow related expenses	459,000
Future payments	$ 500,000
Lantern Pharma Limited [Member]
Research and development expenses percentage						50%	50%
Research and development expense | £							£ 24,215
Revenues						$ 0
Actuate Therapeutics [Member] | Collaboration Agreement [Member]
Actuate stock of restricted shares | shares		25,000
Nominal value acquired cost		$ 0

Schedule of Balance Sheet Infor

Schedule of Balance Sheet Information Related to Leases (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Leases
Operating lease, right-of-use asset, net	$ 82,918	$ 185,943
Current portion of operating lease liabilities	92,023	152,058
Operating lease liabilities, net of current portion		52,890
Total operating lease liabilities	$ 92,023	$ 204,948

Schedule of Future Estimated Mi

Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Leases
2022 (remaining three months)	$ 40,052
2023	53,403
Total minimum lease payments	93,455
Less amount representing interest	(1,432)
Present value of future minimum lease payments	92,023	$ 204,948
Less current portion of operating lease liabilities	92,023	152,058
Operating lease liabilities, net of current portion		$ 52,890

Schedule of Other Supplemental

Schedule of Other Supplemental Information Related to Operating Leases (Details)	Sep. 30, 2022	Sep. 30, 2021
Leases
Weighted average remaining term of operating leases (in years)	6 months 29 days	1 year 6 months 29 days
Weighted average discount rate of operating leases	4.65%	4.65%

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Leases
General and administrative expenses	$ 30,000	$ 38,000	$ 108,000	$ 67,000
Lease expiration date			The leases expire in April 2023

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - $ / shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Equity [Abstract]
Number of shares, outstanding beginning	890,826
Weighted average exercise price per share, outstanding beginning	$ 6.54
Number of shares, granted	155,000
Weighted average exercise price per share, granted	$ 5.79
Number of shares, exercised	(32,538)
Weighted average exercise price per share, exercised	$ 1.03
Number of shares, cancelled or expired	(12,335)	(22,238)
Weighted average exercise price per share, cancelled or expired	$ 13.79
Number of shares, outstanding ending	1,000,953
Weighted average exercise price per share, outstanding ending	$ 6.52

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended				9 Months Ended		12 Months Ended
	Jan. 20, 2021	Aug. 31, 2022	Nov. 30, 2021	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]
Issuance of stock, value							$ 64,166,854
Proceeds from warrants exercise								$ 300,000	$ 61,000
Exercise price				$ 3.13				$ 3.13
Repurchase of shares, value					$ 2,482,286
Common stock, shares authorized				25,000,000				25,000,000		25,000,000
Common stock, shares issued				10,857,040				10,857,040		11,088,835
Common stock, shares outstanding				10,857,040				10,857,040		11,088,835
Purchase of warrants				177,998				177,998		273,777
Weighted average exercise price				$ 6.52				$ 6.52		$ 6.54
Stock-based compensation								$ 857,650	$ 715,616
Number of shares, exercised								32,538
Number of shares, granted								155,000
Number of shares, cancelled or expired								12,335	22,238
Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Expiration date of warrants								Mar. 07, 2024		Mar. 17, 2022
Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Expiration date of warrants								Jun. 10, 2025		Jun. 10, 2025
Equity Option [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of stock, shares						0			11,782
Share price						$ 1.03			$ 1.03
Issuance of stock, value									$ 12,000
Stock-based compensation				$ 301,000		$ 224,000		$ 858,000	$ 716,000
Number of shares, exercised									11,782
Number of shares, granted									0
Panna Sharma [Member]
Subsidiary, Sale of Stock [Line Items]
Weighted average exercise price		$ 5.60
Number of shares, granted		100,000
Share price		$ 15
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of stock, shares							4,928,571
Issuance of stock, value							$ 493
Repurchase of shares					353,667
Repurchase of shares, value					$ 36
Weighted average exercise price				$ 5.59				$ 5.59
Number of shares, exercised				26,093				715,782
Common Stock [Member] | Director [Member]
Subsidiary, Sale of Stock [Line Items]
Repurchase of shares			7,000,000	0				353,667
Repurchase of shares, value								$ 2,482,000
Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of stock, shares				0		0		95,779	19,367
Weighted average exercise price				$ 9.27				$ 9.27		$ 7.12
Cashless Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of stock, shares				26,093		2,960		26,093	6,352
Warrants to purchase shares				32,538		3,832		32,538	8,047
Exercise price						$ 3.13			$ 3.13
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Gross proceeds	$ 69,000,000
Net proceeds	64,167,000
Proceeds after deducting underwriting discounts and commissions	4,554,000
Other offering expenses	279,000
Deferring offering costs	$ 101,000
IPO [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of stock, shares	4,928,571
Share price	$ 14
Over-Allotment Option [Member] | Common Stock [Member] | Underwriters [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of stock, shares	642,856

Schedule of Contractual Maturit

Schedule of Contractual Maturities Investments of Marketable Securities (Details)	Sep. 30, 2022 USD ($)
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Marketable securities aggregate fair value	$ 13,100,175
Due within one year	4,669,099
Due in one to two years	6,700,963
Due in two to five years	1,730,113
Total	13,100,175
Government & Agency Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Marketable securities amortized cost	5,410,239
Marketable securities unrealized gains	77
Marketable securities unrealized losses	(208,545)
Marketable securities aggregate fair value	5,201,771
Total	5,201,771
Corporate Bonds [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Marketable securities amortized cost	8,177,653
Marketable securities unrealized gains
Marketable securities unrealized losses	(279,249)
Marketable securities aggregate fair value	7,898,404
Total	7,898,404
Marketable Securities - Debt [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Marketable securities amortized cost	13,587,892
Marketable securities unrealized gains	77
Marketable securities unrealized losses	(487,794)
Marketable securities aggregate fair value	13,100,175
Total	13,100,175
Mutual Funds - Fixed Income [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Marketable securities amortized cost	4,002,704
Marketable securities unrealized gains
Marketable securities unrealized losses	(334,004)
Marketable securities aggregate fair value	3,668,700
Total	3,668,700
Mutual Funds - Alternative Investments [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Marketable securities amortized cost	2,023,154
Marketable securities unrealized gains
Marketable securities unrealized losses	(223,304)
Marketable securities aggregate fair value	1,799,850
Total	1,799,850
Marketable Securities - Mutual Funds [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Marketable securities amortized cost	6,025,858
Marketable securities unrealized gains
Marketable securities unrealized losses	(557,308)
Marketable securities aggregate fair value	5,468,550
Total	$ 5,468,550

Schedule of Gross Unrealized Lo

Schedule of Gross Unrealized Losses and Fair Values for Marketable Securities (Details)	Sep. 30, 2022 USD ($)
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Fair Value Less than 12 months	$ 4,622,180
Unrealized Loss Less than 12 months	(258,865)
Fair Value More than 12 months	13,201,330
Unrealized Loss More than 12 months	(786,237)
Government & Agency Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Fair Value Less than 12 months	1,455,466
Unrealized Loss Less than 12 months	(54,070)
Fair Value More than 12 months	3,001,090
Unrealized Loss More than 12 months	(154,475)
Corporate Bonds [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Fair Value Less than 12 months	1,330,714
Unrealized Loss Less than 12 months	(34,791)
Fair Value More than 12 months	6,567,690
Unrealized Loss More than 12 months	(244,458)
Mutual Funds - Fixed Income [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Fair Value Less than 12 months	1,836,000
Unrealized Loss Less than 12 months	(170,004)
Fair Value More than 12 months	1,832,700
Unrealized Loss More than 12 months	(164,000)
Mutual Funds - Alternative Investments [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Fair Value Less than 12 months
Unrealized Loss Less than 12 months
Fair Value More than 12 months	1,799,850
Unrealized Loss More than 12 months	$ (223,304)

Marketable Securities (Details

Marketable Securities (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Securities redeemed	$ 900,000	$ 2,570,000
Realized loss	27,000	76,000
Government & Agency Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Securities redeemed	$ 350,000	$ 350,000

Schedule of Assets are Measured

Schedule of Assets are Measured at Fair Value On a Recurring Basis (Details)	9 Months Ended
	Sep. 30, 2022 USD ($)
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis	$ 18,568,725
NAV [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis	1,799,850
Fair Value, Inputs, Level 1 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis
Fair Value, Inputs, Level 2 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis	16,768,875
Fair Value, Inputs, Level 3 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis
Government & Agency Securities [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis	5,201,771
Government & Agency Securities [Member] | NAV [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis
Government & Agency Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis
Government & Agency Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis	5,201,771
Government & Agency Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis
Corporate Bond Securities [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis	7,898,404
Corporate Bond Securities [Member] | NAV [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis
Corporate Bond Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis
Corporate Bond Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis	7,898,404
Corporate Bond Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis
Mutual Funds - Fixed Income [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis	3,668,700
Mutual Funds - Fixed Income [Member] | NAV [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis
Mutual Funds - Fixed Income [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis
Mutual Funds - Fixed Income [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis	3,668,700
Mutual Funds - Fixed Income [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis
Mutual Funds - Alternative Investments [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis	1,799,850
Mutual Funds - Alternative Investments [Member] | NAV [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis	1,799,850
Mutual Funds - Alternative Investments [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis
Mutual Funds - Alternative Investments [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis
Mutual Funds - Alternative Investments [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair value recurring basis

Notes and Loan Payable (Details

Notes and Loan Payable (Details Narrative)	May 01, 2020 USD ($)
Debt Disclosure [Abstract]
Aggregate loan amount	$ 108,500
Description of notes and loan payable	the PPP Loan bore interest at a fixed rate of one percent (1.0%) per annum. Payments of principal and interest were deferred for the first six months following the Origination Date, and the PPP Loan provided that it would mature two years after the Origination Date. The guidance under the Paycheck Protection Program was later updated so that payments of principal and interest were extended past the current fiscal year and maturity was extended past two years.
Annual interest rate	1%

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Outstanding Diluted Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,178,951	1,099,792
Warrants To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	177,998	298,204
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,000,953	801,588